Bowen Hanes & Co. Inc. Buys 23,500 Shares of Elanco Animal Health Incorporated $ELAN

Bowen Hanes & Co. Inc. raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 0.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,647,270 shares of the company’s stock after purchasing an additional 23,500 shares during the period. Elanco Animal Health accounts for approximately 1.6% of Bowen Hanes & Co. Inc.’s investment portfolio, making the stock its 29th biggest position. Bowen Hanes & Co. Inc. owned approximately 0.53% of Elanco Animal Health worth $63,349,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ELAN. UBS Group AG raised its holdings in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares during the period. Sei Investments Co. boosted its holdings in shares of Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after acquiring an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. grew its position in shares of Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after purchasing an additional 3,717,404 shares during the last quarter. Invesco Ltd. grew its position in shares of Elanco Animal Health by 336.0% in the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after purchasing an additional 3,690,735 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Elanco Animal Health during the first quarter worth approximately $66,390,000. 97.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Morgan Stanley lifted their target price on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $28.73.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 4,971 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Rajeev A. Modi bought 4,911 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $24.78 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 12 month low of $13.39 and a 12 month high of $27.72. The firm has a market cap of $12.38 billion, a P/E ratio of -49.56, a P/E/G ratio of 1.66 and a beta of 1.68. The company’s 50-day moving average price is $23.91 and its two-hundred day moving average price is $23.97.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm’s quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, analysts anticipate that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.